Sower - very good points - Thanks
Imo it is important that the company soon can prove some sales success. Whatever happens otherwise (AMEX delisting or not, I don't really care about this honestly) the only thing which matters is whether revenues start to flow very soon or not. For the beginning, just a small evidence that someone wants to buy at least some rapid tests would be enough already. We know that there are good distributors who like to sell the tests, which is a very good sign, but the next step is now that some health organizations like to use the tests too and pay for them (proof-of-concept).
BED is a different story. I feel there is enough evidence already that the market will purchase this incidence tool. The only question is if the company will achieve the projected multi-million sales numbers in the future and how fast sales will develop.
I listened into this session with Rick Brounstein at the BIO CEO & Investors Conference recently and it seems to me that Rick is generally a well-respected person in the financing arena so we have good personel which won't hurt us. Nevertheless he won't be able to "produce cash on the Xerox machine".
We see other companies getting more and more revenues in Africa these days (e.g. Chembio) and of course Calypte won't have infinite time to take its share of this market.
China might be a bit different which is a much bigger and less "ripe" market than Africa in my opinion. Anyway, I'm wondering about the Chinese joint venture and its ability to do the marketing in China. Will Marr be some sort of rainmaker ? Marr is probably experienced in doing business in China in a general sense but who is doing the distribution there ? Do we still need an extra Chinese distributor? Who will be our expert in the Chinese diagnostics business? Marr won't be it imo. Do we still need a partner in China ?
An extra problem in this connection is that it obviously takes so much time to get all those market approvals for the diverse countries. I really respect that this is a painful task and there is sure no reason to blame the company for any delay but it is critical nonetheless. This also must happen soon (Kenya, Tansania, South Africa, Philippines, Malaysia, Vietnam, Zimbabwe, Botswana, just to name a few where regulatory activity has been announced some time ago).
The company will be taken serious by the markets when one day there is a person who dares to come up publically with a sales projection for the next couple of years, a concrete plan in other words. That is why a new CEO might be a significant move.
Of course the lack of approvals prevents the company to give predictions. But I would be interested to hear what kind of sales numbers (rapids) the company expects in Uganda in 2006.
Just some extra thoughts of mine.
Cal
News 
Market Data 
Discover 
